Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers

Sam Gandy

doi:10.1016/j.molmed.2023.04.007

Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers

Trends Mol Med. 2023 Jul;29(7):487-488. doi: 10.1016/j.molmed.2023.04.007. Epub 2023 May 9.

Author

Sam Gandy¹

Affiliation

¹ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; James J Peters VA Medical Center, Bronx, NY 10468, USA. Electronic address: samuel.gandy@mssm.edu.

PMID: 37169660
DOI: 10.1016/j.molmed.2023.04.007

Abstract

Alcadeins are among the 90 known substrates for γ-secretase, the aspartyl proteinase complex that liberates the amyloid β (Aβ) peptide by intramembranous cleavage of the ß-carboxy terminal fragment of the Alzheimer's amyloid precursor protein (APP). A new study by Hata et al. provides some surprising results regarding a potential role for alcadeins and their fragments in the prevention and/or treatment of the dementia of Alzheimer's disease (AD).

Keywords: Alzheimer's disease; alcadein; amyloid; oligomer; positron emission tomography.

MeSH terms

Alzheimer Disease* / metabolism
Amyloid Precursor Protein Secretases / metabolism
Amyloid beta-Peptides / metabolism
Amyloid beta-Protein Precursor / metabolism
Brain / metabolism
Humans
Intercellular Signaling Peptides and Proteins / metabolism

Substances

Amyloid beta-Peptides
peptide P3
Amyloid beta-Protein Precursor
Intercellular Signaling Peptides and Proteins
Amyloid Precursor Protein Secretases